+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Comparison of hematologic toxicity between 3DCRT and IMRT planning in cervical cancer patients after concurrent chemoradiotherapy: a national multi-center study



Comparison of hematologic toxicity between 3DCRT and IMRT planning in cervical cancer patients after concurrent chemoradiotherapy: a national multi-center study



European Journal of Gynaecological Oncology 35(1): 62-66



To compare the incidence and severity of acute and chronic hematologic toxicity (HT) in patients treated with three-dimensional conformal radiotherapy (3DCRT) and intensity modulated radiotherapy (IMRT) for curative treatment of cervical cancer and to ascertain the dosimetric parameters of two techniques associated with acute and chronic HT. A total of 127 patients with cervical cancer receiving concomitant pelvic radiotherapy (RT) and cisplatin were evaluated. Pelvic bone marrow (BM) was contoured for each patient and divided into five sub-regions: lumbosacrum (LS), ilium (IL), lower pelvis (LP), pelvis (P), and whole pelvis (WP). The volume of each BM region receiving 10, 20, 30, and 40 Gy was calculated (V10, -V20, -V30, and -V40). The lowest level of hemoglobin, leukocyte, neutrophil, and platelet counts were obtained during chemoradiotherapy and six months after RT. The nadir values were graded according to Common Terminology Criteria for Adverse Events (version 3.0). Grade 2 or greater acute anemia, leukopenia, neutropenia, thrombocytopenia was observed in 2%, 41.5%, 12% ,and 0% in 3DCRT group and in 27%, 53%, 24.5%, and 4.5% in IMRT group, respectively. Grade 2 or greater chronic anemia, leukopenia, neutropenia, and thrombocytopenia was observed in 11%, 10%, 6%, and 0% in 3DCRT group and in 11%, 9%, 4.5%, and 0% in IMRT group, respectively. LS-V30, 40; IL-V10, 20, 30, 40; LP-V10, 20 ,40; P-V10, 20, 30, 40, and TP-V10, 20, 30, 40 were significantly reduced with IMRT planning compared to 3DCRT planning. Logistic regression analysis of potential predictors showed that none of the dosimetric parameters were significant for predicting acute and chronic HT. The present findings showed that IMRT planning reduced irradiated BM volumes compared to 3DCRT planning. However, no difference between the two techniques was observed in terms of acute and chronic HT. Further studies are needed to confirm these results.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 052235400

Download citation: RISBibTeXText

PMID: 24654465


Related references

Correlations Between Radiation Dose in Bone Marrow and Hematological Toxicity in Patients With Cervical Cancer: A Comparison of 3DCRT, IMRT, and RapidARC. International Journal of Gynecological Cancer 26(4): 770-776, 2017

Association between bone marrow dosimetric parameters and acute hematologic toxicity in cervical cancer patients undergoing concurrent chemoradiotherapy: comparison of three-dimensional conformal radiotherapy and intensity-modulated radiation therapy. International Journal of Gynecological Cancer 24(9): 1648-1652, 2015

Association Between Bone Marrow Dosimetric Parameters and Acute Hematologic Toxicity in Locally Advanced Rectal Cancer Patients Treated with Concurrent Weekly Irinotecan in Combination with Capecitabine-Based Chemoradiotherapy and Neoadjuvant Imrt. International Journal of Radiation Oncology*Biology*Physics 102(3): e24-e25, 2018

A comparison of concurrent chemoradiotherapy and radiotherapy in Chinese patients with locally advanced cervical carcinoma: a multi-center study. Radiation Oncology 9: 212, 2015

Radiation-related predictors of hematologic toxicity after concurrent chemoradiation for cervical cancer and implications for bone marrow-sparing pelvic IMRT. International Journal of Radiation Oncology, Biology, Physics 79(4): 1043-1047, 2011

EP-1040: Dosimetric comparison of 3DCRT, IMRT and Carotid sparing IMRT in breast cancer patients. RadioTherapy and Oncology 106: S397-S398, 2013

Acute hematologic and mucosal toxicities in head and neck cancer patients undergoing chemoradiotherapy: a comparison of 3D-CRT, IMRT, and helical tomotherapy. Technology in Cancer Research and Treatment 12(5): 383-389, 2015

Feasibility and acute toxicity of Concurrent Chemoradiotherapy (CCRT) with high-dose rate intracavitary brachytherapy (HDR-ICBT) and 40-mg/m2 weekly cisplatin for Japanese patients with cervical cancer: results of a Multi-Institutional Phase 2 Study (JGOG1066). International Journal of Gynecological Cancer 22(8): 1420-1426, 2013

Acute Hematologic Toxicity and Long-Term Treatment Outcome of Concurrent Chemoradiation Therapy With Weekly Cisplatin and Paclitaxel in Patients With FIGO Stage IB2-IIIb Intact Cervical Cancer: A Single-Center Phase II Clinical Trial. International Journal of Radiation Oncology*biology*physics 96(2): S12-S13, 2016

Normal tissue complication probability modeling of acute hematologic toxicity in cervical cancer patients treated with chemoradiotherapy. International Journal of Radiation Oncology, Biology, Physics 79(3): 800-807, 2011

Early response of patients undergoing concurrent chemoradiotherapy for cervical cancer: a comparison of PET/CT and MRI. Annals of Nuclear Medicine 27(1): 37-45, 2013

S-l combined with cisplatin plus concurrent chemoradiotherapy versus cisplatin plus concurrent chemoradiotherapy for Chinese patients with advanced gastric cancer: a multi-centre randomized controlled trial. Clinical and Translational Oncology 18(7): 672-676, 2017

Early treatment response of patients undergoing concurrent chemoradiotherapy for cervical cancer: An evaluation of integrated multi-parameter Pet-Ivim Mr. European Journal of Radiology 117: 1-8, 2019

Correlation between radiation dose to ¹⁸F-FDG-PET defined active bone marrow subregions and acute hematologic toxicity in cervical cancer patients treated with chemoradiotherapy. International Journal of Radiation Oncology, Biology, Physics 83(4): 1185-1191, 2012

Transforming Growth Factor-Beta1 Polymorphism (-509 C>T) and Late Rectal or Genitourinary Toxicity in Prostate Cancer Patients after 3DCRT or IMRT. International Journal of Radiation Oncology*biology*physics 78(3): S664-S665, 2010